Search. Read. Cite.

Easy to search. Easy to read. Easy to cite with credible sources.

Alzheimer`s & Dementia

Year: 2011  |  Volume: 7  |  Issue: 3  |  Page No.: 270 - 279

The diagnosis of mild cognitive impairment due to Alzheimer‘s disease: Recommendations from the National Institute on Aging-Alzheimer‘s Association workgroups on diagnostic guidelines for Alzheimer's disease

Reisa A. Sperling, Paul S. Aisen, Laurel A. Beckett, Laurel A. Beckett, Suzanne Craft, Anne M. Fagan, Takeshi Iwatsubo, Clifford R. Jack, Jeffrey Kaye, Thomas J. Montine, Denise C. Park, Eric M. Reiman, Christopher C. Rowe, Eric Siemers, Yaakov Stern, Yaakov Stern, Maria C. Carrillo, Bill Thies, Marcelle Morrison- Bogorad, Molly V. Wagster and Creighton H. Phelps

Abstract

The National Institute on Aging and the Alzheimer‘s Association charged a workgroup with the task of developing criteria for the symptomatic predementia phase of Alzheimer‘s disease (AD), referred to in this article as mild cognitive impairment due to AD. The workgroup developed the following two sets of criteria: (1) core clinical criteria that could be used by healthcare providers without access to advanced imaging techniques or cerebrospinal fluid analysis, and (2) research criteria that could be used in clinical research settings, including clinical trials. The second set of criteria incorporate the use of biomarkers based on imaging and cerebrospinal fluid measures. The final set of criteria for mild cognitive impairment due to AD has four levels of certainty, depending on the presence and nature of the biomarker findings. Considerable work is needed to validate the criteria that use biomarkers and to standardize biomarker analysis for use in community settings.

View Fulltext